Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: PR vs 1st amended complaint

From the PR

Pursuant to the 2005 Commercialization Agreement, TPL can and is continuing to pursue licenses within the scope of the Preliminary Injunction

From the 1st amended complaint

1. TPL’s response has been to threaten to shut down the licensing program. Further to try to coerce Patriot to loan it more money, TPL has focused on a new strategy of improperly diverting licensing revenue to itself through its licensing division Alliacense, contrary to its authority under the ComAg

Share
New Message
Please login to post a reply